AT
AtG develops novel small molecule drug candidates and associated biomarkers to target cancer metabolic adaptation. Their approach focuses on overcoming tumor vulnerabilities in both treatment-naïve and resistant cancer patients. The company aims to advance its therapeutic portfolio into clinical trials to improve outcomes for advanced cancer patients.
Updated 4 months ago
Funding
$720K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- AtG develops novel small molecule drug candidates and associated biomarkers to target cancer metabolic adaptation. Their approach focuses on overcoming tumor vulnerabilities in both treatment-naïve and resistant cancer patients. The company aims to advance its therapeutic portfolio into clinical trials to improve outcomes for advanced cancer patients.